Nonetheless, prescribing GLP‐1 receptor agonists amid the COVID‐19 pandemic should not be discouraged, as they can provide both cardioprotective and renoprotective benefits in patients with type 2 diabetes.24, 25. Here, GLP1R is linked to type 2 diabetes mellitus.